GMED - Globus Medical, Inc.
Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union
Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.
The mean of analysts' price targets for Globus Medical (GMED) points to a 25% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Integer (ITGR). But which of these two stocks is more attractive to value investors?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
American Capital Management Inc. acquired a new stake in shares of Globus Medical, Inc. (NYSE: GMED) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 653,072 shares of the medical device company's stock, valued at approximately $51,599,000. Globus Medical
AUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University. With a mission to transform healthcare experience through digital innovation, Higgs Boson will position Globus Medical to shape patient and provider experience throughout the full episode of care.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
PEG-driven GARP picks EnerSys, Globus Medical, DoubleVerify and Match Group pair discounted valuations with strong growth potential.
Globus Medical is rated a buy, targeting a 17.5% return over four quarters with a constant 10.56x EV/EBITDA multiple. GMED's base business is compounding faster than headline growth, with international sales rising 18% and gross margin expanding by 200bps, excluding accounting effects. SG&A leverage drove operating margin improvement, while integration of Nevro remains a known, sized, and management-dated drag.
Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Globus Medical (GMED) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Integer (ITGR). But which of these two stocks is more attractive to value investors?
Globus Medical NYSE: GMED reported second-quarter 2026 revenue of $789.6 million, up 6% from a year earlier, as growth in its spine and trauma businesses helped offset declines in enabling technologies and Nevro sales. The company reaffirmed its full-year revenue outlook while raising its adjusted earnings forecast, citing margin expansion and operating leverage in the first half.
Globus Medical raises 2026 EPS guidance after Q2 margin gains and spine growth while holding sales guidance steady amid Nevro and Enabling Technologies risks.
While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Globus Medical, Inc. (GMED) Q2 2026 Earnings Call Transcript
AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amundi raised its position in Globus Medical, Inc. (NYSE: GMED) by 12.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,520 shares of the medical device company's stock after purchasing an additional 8,126 shares during the quarter.